Financial Times August 3, 2020
Data suggest investors are regaining confidence in backing development of new treatments
Charles Cathlin, chief executive of TruGenomix, spent the lockdown months trying to convince investors that his start-up can transform the treatment of post-traumatic stress disorder. The condition, often associated with combat veterans, looks likely to affect many healthcare workers coping with Covid-19.
The former air force captain first became interested in how we care for people’s mental health after helping to co-ordinate the emergency response to the 9/11 terrorist attacks on the US in 2001. Now, his country — and the world — face another crisis that could leave people suffering for years to come.
But even armed with an unusual technology for detecting PTSD using...
Today's Sponsors
Today's Sponsor